

pre|CISION™ technology

Tumour microenvironment-targeted cancer therapies that transform patient outcomes

DELIVERING NEXT-GENERATION TARGETED DRUG TECHNOLOGIES

pre|CISION™ is Avacta's proprietary technology platform, enabling first-in-class cancer therapies that boost efficacy and minimise off-target toxicity.

pre|CISION™ releases active drug only within the tumour microenvironment – limiting systemic exposure and enhancing the safety and therapeutic potential of treatments for oncology indications.


Incorporating a substrate that is sensitive to cleavage by fibroblast activation protein (FAPα), pre|CISION™ is innovating an FAPα-activated approach to delivering cancer therapies – preventing the drug from entering cells and rendering it inert until the substrate is cleaved in the tumour microenvironment. In this way, systemic exposure to the therapy is dramatically reduced, and the safety and therapeutic window of powerful anti-cancer treatments is improved.

The high modularity of the platform offers the potential to use the precision substrate on a range of therapeutic agents for the next generation of targeted drug technologies.

AVACTA THERAPEUTICS

Avacta Therapeutics is a clinical-stage pioneer of next-generation cancer therapies, with a mission to transform treatment outcomes for cancer patients.

Avacta's novel cancer therapies harness its proprietary technology – the innovative pre|CISION™ platform for tumour-targeted chemotherapy and novel Affimer® biotherapeutics platform – to deliver first-in-class cancer therapies that boost efficacy and minimise off-target toxicity. With this approach, Avacta is building a pipeline of novel cancer therapies with the potential to revolutionise the treatability of solid tumours.




pre|CISION™ AT A GLANCE

Key advantages

- Tumour targeting – localised release of therapeutic agents in the tumour, including chemotherapies, small molecules and other agents
- FAPα-activated form of chemotherapies – limiting systemic exposure
- Potential to significantly increase safety and therapeutic potential of cancer treatments

pre|CISION™



Now in clinic: Avacta's lead pre|CISION™ programme, AVA6000 – a tumour-activated form of a chemotherapeutic agent, doxorubicin.

For more information:
www.avacta.com/therapeutics